267 related articles for article (PubMed ID: 33901270)
1. Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance.
Huang-Doran I; Kinzer AB; Jimenez-Linan M; Thackray K; Harris J; Adams CL; de Kerdanet M; Stears A; O'Rahilly S; Savage DB; Gorden P; Brown RJ; Semple RK
J Clin Endocrinol Metab; 2021 Jul; 106(8):2367-2383. PubMed ID: 33901270
[TBL] [Abstract][Full Text] [Related]
2. Massive Ovarian Growth in a Woman With Severe Insulin-Resistant Polycystic Ovary Syndrome Receiving GnRH Analogue.
Singh P; Agress A; Madrigal VK; Magyar C; Ostrzega N; Chazenbalk GD; Dumesic DA
J Clin Endocrinol Metab; 2019 Jul; 104(7):2796-2800. PubMed ID: 30759233
[TBL] [Abstract][Full Text] [Related]
3. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
[TBL] [Abstract][Full Text] [Related]
4. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome.
Lungu AO; Zadeh ES; Goodling A; Cochran E; Gorden P
J Clin Endocrinol Metab; 2012 Feb; 97(2):563-7. PubMed ID: 22090274
[TBL] [Abstract][Full Text] [Related]
6. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
Patlolla S; Vaikkakara S; Sachan A; Venkatanarasu A; Bachimanchi B; Bitla A; Settipalli S; Pathiputturu S; Sugali RN; Chiri S
Gynecol Endocrinol; 2018 Mar; 34(3):238-242. PubMed ID: 29068242
[TBL] [Abstract][Full Text] [Related]
7. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Nestler JE; Powers LP; Matt DW; Steingold KA; Plymate SR; Rittmaster RS; Clore JN; Blackard WG
J Clin Endocrinol Metab; 1991 Jan; 72(1):83-9. PubMed ID: 1898744
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
[TBL] [Abstract][Full Text] [Related]
9. Excess 11-Oxygenated Androgens in Women With Severe Insulin Resistance Are Mediated by Adrenal Insulin Receptor Signaling.
Walzer D; Turcu AF; Jha S; Abel BS; Auchus RJ; Merke DP; Brown RJ
J Clin Endocrinol Metab; 2022 Aug; 107(9):2626-2635. PubMed ID: 35696182
[TBL] [Abstract][Full Text] [Related]
10. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
[TBL] [Abstract][Full Text] [Related]
11. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
13. Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
Lin XF; Wu RR; Du J; Liao YC; Du Y; Ye Y; Wang Y; Zhang XB; Wu C; Chen A
Clin Exp Obstet Gynecol; 2015; 42(3):315-20. PubMed ID: 26152001
[TBL] [Abstract][Full Text] [Related]
14. Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; Prontera O; Fanelli F; Ciampaglia W; Cognigni GE; Pagotto U; Pasquali R
J Endocrinol Invest; 2011 Oct; 34(9):685-91. PubMed ID: 21586896
[TBL] [Abstract][Full Text] [Related]
15. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
Garmes HM; Tambascia MA; Zantut-Wittmann DE
Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779
[TBL] [Abstract][Full Text] [Related]
16. Effects of chronic hyperandrogenism and/or administered central nervous system insulin on ovarian manifestation and gonadotropin and steroid secretion.
Allon MA; Leach RE; Dunbar J; Diamond MP
Fertil Steril; 2005 Apr; 83 Suppl 1():1319-26. PubMed ID: 15831308
[TBL] [Abstract][Full Text] [Related]
17. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
Nestler JE; Jakubowicz DJ
N Engl J Med; 1996 Aug; 335(9):617-23. PubMed ID: 8687515
[TBL] [Abstract][Full Text] [Related]
18. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism.
Toscano V; Bianchi P; Balducci R; Guglielmi R; Mangiantini A; Lubrano C; Sciarra F
Clin Endocrinol (Oxf); 1992 Feb; 36(2):197-202. PubMed ID: 1533185
[TBL] [Abstract][Full Text] [Related]
19. Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats.
Wu LM; Wang YX; Zhan Y; Liu AH; Wang YX; Shen HF; Wang YF; Wang LY; Tao ZB; Wang YQ
Peptides; 2021 Nov; 145():170624. PubMed ID: 34375684
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
